Personalized Antisense Oligonucleotide (ASO) Therapy

📖 Wiki Page

therapeutic2512 wordssynced 2026-04-02

Personalized Antisense Oligonucleotide (ASO) Therapy

Overview

flowchart TD Personalized_Antisense_Oligonu["Personalized Antisense Oligonucleotide ASO Thera"] Personalized_Antisense_Oligonu["Antisense"] Personalized_Antisense_Oligonu -->|"related to"| Personalized_Antisense_Oligonu style Personalized_Antisense_Oligonu fill:#81c784,stroke:#333,color:#000 Personalized_Antisense_Oligonu["Oligonucleotide"] Personalized_Antisense_Oligonu -->|"related to"| Personalized_Antisense_Oligonu style Personalized_Antisense_Oligonu fill:#81c784,stroke:#333,color:#000 Personalized_Antisense_Oligonu["table"] Personalized_Antisense_Oligonu -->|"related to"| Personalized_Antisense_Oligonu style Personalized_Antisense_Oligonu fill:#81c784,stroke:#333,color:#000 style Personalized_Antisense_Oligonu fill:#4fc3f7,stroke:#333,color:#000

...

Personalized Antisense Oligonucleotide (ASO) Therapy

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Personalized Antisense Oligonucleotide (ASO) Therapy</th>
</tr>
<tr>
<td class="label">Component</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Patient Identification</td>
<td>Genetic screening to identify pathogenic mutations in target genes</td>
</tr>
<tr>
<td class="label">ASO Design</td>
<td>Custom sequence design to selectively target mutant allele</td>
</tr>
<tr>
<td class="label">Preclinical Testing</td>
<td>In vitro and in vivo validation of efficacy and safety</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>GMP-scale synthesis for clinical supply</td>
</tr>
<tr>
<td class="label">Regulatory Strategy</td>
<td>Orphan drug designation, accelerated approval pathways</td>
</tr>
<tr>
<td class="label">Clinical Monitoring</td>
<td>biomarker-driven endpoints, long-term follow-up</td>
</tr>
<tr>
<td class="label">Generation</td>
<td>Modification</td>
</tr>
<tr>
<td class="label">First</td>
<td>Phosphorothioate (PS) backbone</td>
</tr>
<tr>
<td class="label">Second</td>
<td>2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE)</td>
</tr>
<tr>
<td class="label">Third</td>
<td>Locked Nucleic Acid (LNA), Peptide Nucleic Acid (PNA), PMO</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Values</td>
</tr>
<tr>
<td class="label">Injection Volume</td>
<td>5-15 mL</td>
</tr>
<tr>
<td class="label">Dosing Frequency</td>
<td>Every 4-12 weeks</td>
</tr>
<tr>
<td class="label">CSF Half-life</td>
<td>2-4 weeks</td>
</tr>
<tr>
<td class="label">Brain Tissue Exposure</td>
<td>Dose-dependent, 3-6 months</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Duration</td>
</tr>
<tr>
<td class="label">Target Validation</td>
<td>2-4 months</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>3-6 months</td>
</tr>
<tr>
<td class="label">Regulatory</td>
<td>3-6 months</td>
</tr>
<tr>
<td class="label">Cost Component</td>
<td>Estimated Amount</td>
</tr>
<tr>
<td class="label">Development Cost</td>
<td>$50-100 million</td>
</tr>
<tr>
<td class="label">Manufacturing (per batch)</td>
<td>$1-3 million</td>
</tr>
<tr>
<td class="label">Annual Treatment Cost</td>
<td>$200,000-500,000</td>
</tr>
<tr>
<td class="label">Lifetime Treatment (10 years)</td>
<td>$2-5 million</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">NCT05318985 (Bepranemab)</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">NCT05615614 (DOES NOT EXIST) (E2814)</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">NCT04539041 (NIO752)</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">NCT07221344 (ARO-MAPT)</td>
<td>Arrowhead</td>
</tr>
</table>

Personalized Antisense Oligonucleotide (ASO) Therapy represents a transformative approach to treating rare neurodegenerative diseases by tailoring RNA-targeted interventions to individual patients based on their genetic profiles. This paradigm, pioneered by [Ionis Pharmaceuticals](/companies/ionis), enables the development of patient-specific ASOs for diseases with known genetic causes that were previously considered untreatable. Unlike traditional drug development that creates one-size-fits-all treatments, personalized ASO therapy identifies the specific genetic mutation driving a patient's disease and designs a custom oligonucleotide to selectively target and reduce the expression of that pathogenic protein.

The concept gained prominence through the successful development of "n-of-1" ASO therapies for ultra-rare neurological disorders, demonstrating that individual patients with deterministic genetic mutations can benefit from precisely targeted interventions["@crooke2018"]. For [corticobasal syndrome (CBS)](/diseases/corticobasal-degeneration) and [progressive supranuclear palsy (PSP)](/diseases/progressive-supranuclear-palsy), which are 4R-tauopathies lacking effective disease-modifying treatments, personalized ASO therapy offers a promising avenue to target the underlying tau protein dysregulation that drives these devastating conditions["@brunden2020"].

The IONIS Personalized Medicine Model

Concept and Approach

The IONIS personalized medicine model represents a systematic approach to developing ASO therapies for patients with rare genetic neurodegenerative diseases. Unlike conventional drug development that targets large patient populations, this model focuses on individual patients or small cohorts with specific pathogenic mutations[@koch2023]. The process begins with comprehensive genetic sequencing to identify the exact mutation causing the patient's disease, followed by ASO design to selectively target the mutant transcript while sparing wild-type expression where possible.

Ionis has established partnerships with leading medical centers to identify patients with ultra-rare genetic neurodegenerative diseases and develop customized ASO therapies through an accelerated development pathway[@ionisa]. This approach has been particularly successful for children with spinal muscular atrophy (SMA) and other rare neurological conditions where the genetic cause is well-characterized. The company's "legacy" programs have treated over 100 patients with personalized ASOs under expanded access programs, generating critical safety and efficacy data that have informed subsequent clinical development[@finkel2017].

Key Components of the IONIS Model

Mechanism of Action

ASO Chemistry and Design

Antisense oligonucleotides are short, single-stranded DNA or RNA molecules typically 12-25 nucleotides in length that bind to complementary messenger RNA (mRNA) sequences through Watson-Crick base pairing[@bennett2023]. Once bound, ASOs utilize several mechanisms to modulate gene expression:

RNase H-Mediated Degradation: The most common mechanism involves DNA-based ASOs forming DNA-RNA hybrids with target mRNA. RNase H recognizes these hybrids and cleaves the RNA strand, leading to degradation of the target transcript and reduced protein translation[@crooke2022]. This mechanism is particularly effective for reducing expression of toxic proteins in neurodegeneration.

Steric Block Splicing Modulation: ASOs can also bind to pre-mRNA to modify splicing patterns. By blocking splice sites or regulatory sequences, ASOs can promote exon inclusion or skipping, restoring proper protein function in diseases caused by aberrant splicing[@havens2023]. This mechanism is used in nusinersen for SMA, which promotes inclusion of exon 7 in SMN2 transcripts.

Translational Blocking: Some ASOs act as steric blocks to prevent ribosomal translation without degrading the mRNA. This approach allows for fine-tuned reduction of protein expression when partial knockdown is desired[@rinaldi2024].

Chemical Modifications

The therapeutic utility of ASOs depends critically on chemical modifications that enhance stability, delivery, and tissue specificity:

Modern clinical ASOs typically combine multiple modifications to optimize their pharmacological properties. The 2'-MOE chemistry used in many CNS ASOs provides a favorable balance of nuclease resistance, tissue distribution, and tolerability[@geary2019].

Target Selection for CBS/PSP

Genetic Factors

For [corticobasal syndrome](/diseases/corticobasal-degeneration) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), identifying actionable genetic targets remains a significant challenge due to the primarily sporadic nature of these disorders. However, several genetic factors influence disease risk and may provide targets for personalized ASO therapy:

MAPT Mutations: The [MAPT gene](/genes/mapt) encodes the [tau protein](/proteins/tau), and specific mutations in the tau gene are known to cause familial tauopathies including certain forms of PSP and CBD[@litvan2023]. While these mutations account for only a small fraction of cases, patients with MAPT mutations represent a clear target population for tau-reducing ASOs.

4R-Tau Dysregulation: Even in sporadic cases, the fundamental pathology involves selective accumulation of 4-repeat (4R) tau isoforms. ASOs targeting alternative splicing of [MAPT](/proteins/mapt) pre-mRNA to shift the 3R:4R ratio toward normal represents a potential strategy applicable to broader patient populations[@wszolek2022].

Biomarker-Driven Patient Selection

Effective personalized ASO therapy for tauopathies requires robust biomarker selection criteria:

Tau PET Imaging: Confirms presence of tau pathology and quantifies burden

CSF Tau Levels: Total tau, phosphorylated tau (p-tau181, p-tau217) as pharmacodynamic biomarkers

Genetic Panel: Identifies pathogenic [MAPT](/genes/mapt) mutations or risk variants

Clinical Phenotype: CBS vs PSP vs CBD differentiation affects treatment selection

Delivery Methods

Intrathecal Administration

Intrathecal (IT) delivery directly into the cerebrospinal fluid (CSF) remains the gold standard for CNS-directed ASO therapy. This route bypasses the [blood-brain barrier](/mechanisms/blood-brain-barrier-biology) and achieves higher concentrations in the brain and spinal cord compared to systemic delivery[@ackermann2022].

Procedure: Lumbar puncture allows direct injection into the CSF space. The ASO distributes throughout the CNS via CSF circulation, with distribution to brain tissue occurring over several days to weeks.

Dosing: Typical intrathecal ASO dosing involves loading doses (multiple injections over weeks) followed by maintenance doses every 1-3 months. This regimen maintains therapeutic concentrations in the CSF and central nervous system tissue[@miller2020].

Alternative Delivery Approaches

While intrathecal delivery remains the standard, several alternative approaches are under development to improve patient convenience and tissue distribution:

Conjugated ASOs: Chemical conjugation to ligands that engage endogenous transport systems can enable systemic delivery while maintaining CNS activity. Examples include:

GalNAc conjugates: Target ASOs to liver (peripheral applications)
CPPs (Cell-Penetrating Peptides): Facilitate cellular uptake
Antibody-ASO conjugates: Target specific cell types or receptors[@tanowitz2023]

Intranasal Delivery: Direct nose-to-brain delivery is being explored for ASOs, potentially avoiding the need for lumbar punctures. Early preclinical data show promising delivery to CNS structures[@cheng2021].

Novel Formulations: Lipid nanoparticles (LNPs), exosomes, and other delivery vehicles are being engineered to improve ASO distribution and cellular uptake[@juliano2024].

Manufacturing and Production

GMP Manufacturing Process

Personalized ASO manufacturing follows rigorous GMP (Good Manufacturing Practice) standards to ensure safety, purity, and potency. The process involves:

Oligonucleotide Synthesis: Solid-phase synthesis using automated synthesizers with phosphoramidite chemistry. Each nucleotide addition involves coupling, oxidation, and capping steps, with overall synthesis yields of 30-50% for 20-mer ASOs[@anderson2023].

Purification: Crude ASO mixtures are purified using reverse-phase HPLC and/or ion-exchange chromatography to isolate the full-length product from failure sequences and impurities.

Quality Control: Each batch undergoes extensive testing including:

Identity verification (mass spectrometry)
Purity assessment (HPLC, capillary electrophoresis)
Potency testing (in vitro RNase H assay)
Safety testing (endotoxin, sterility)

Timeline and Cost Considerations

The development timeline for a personalized ASO from identification to first patient treatment typically spans 12-24 months:

Estimated Costs:

Preclinical development: $2-5 million
GMP manufacturing (initial): $1-3 million per batch
Annual treatment cost (maintenance): $200,000-500,000
Full clinical development: $50-100 million

Regulatory Pathway

Orphan Drug Designation

For rare diseases like CBS and PSP, the FDA's Orphan Drug Designation provides important incentives for ASO development:

7-year market exclusivity post-approval
Tax credits for clinical testing costs
Regulatory fee waivers for IND and marketing applications
Protocol assistance from FDA during development[@fda]

Accelerated Approval Pathway

The FDA's accelerated approval pathway allows approval based on surrogate endpoints likely to predict clinical benefit, which is particularly relevant for ASO development:

Surrogate Endpoints for Tau ASOs:

CSF tau protein reduction (p-tau181, p-tau217)
Tau PET signal reduction
Neurofilament light chain (NfL) in CSF

The approval of [tofersen (Qalsody](/companies/ionis)) for SOD1-ALS established a precedent for biomarker-based accelerated approval of ASOs in neurodegenerative disease[@fda2023]. This pathway enabled FDA approval based on CSF SOD1 reduction even though the clinical outcomes did not reach statistical significance in the primary analysis.

Special Considerations for Personalized ASOs

N-of-1 Trials: The FDA has shown flexibility in considering data from single-patient studies, particularly for ultra-rare diseases with no available treatments. Expanded access programs have generated safety data from over 100 patients treated with personalized ASOs[@kumar2024].

Companion Diagnostics: Co-development of genetic tests to identify patients who may benefit from therapy is often required, adding complexity and timeline to the development process.

Cost and Accessibility

Current Treatment Economics

The economics of personalized ASO therapy present significant challenges for patient access:

Payment Models and Access

Several models have emerged to address the high costs of personalized ASO therapy:

Outcomes-Based Pricing: Payers reimburse based on demonstrated clinical benefit, with rebates if expected outcomes are not achieved.

Annually Renewable Contracts: Annual review of treatment response determines continued coverage.

Access Programs: Pharmaceutical companies offer expanded access programs for patients meeting specific criteria.

Foundation Support: Patient advocacy organizations provide financial assistance for treatment costs.

Application to CBS/PSP

Current Landscape

No disease-modifying therapies are approved for [corticobasal syndrome](/diseases/corticobasal-degeneration) or [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy). The tau-focused ASO development landscape offers hope for these conditions:

Active Programs:

[BIIB080 (MAPTRx](/therapeutics/biib080-maptrx)) — Ionis/Biogen tau ASO in Phase 2 for AD, with potential extension to PSP
Novel 4R-tau selective ASOs in preclinical development
Splicing modulators targeting MAPT exon 10 to normalize 3R:4R ratio

Challenges for CBS/PSP ASO Development

Sporadic Disease: Unlike SOD1-ALS or SMA, most CBS/PSP cases lack a clear monogenic cause, complicating target identification.

Diagnostic Uncertainty: Clinical differentiation between CBS, PSP, CBD, and other parkinsonian disorders remains challenging.

Endpoint Selection: Clinical trial endpoints for progressive conditions with limited treatment options require careful validation.

Patient Population: Relatively small patient populations challenge traditional clinical trial designs.

Strategic Approaches

Biomarker Enrichment: Use tau PET and CSF biomarkers to identify patients with active tau pathology

Genetic Subsetting: Focus initially on patients with [MAPT](/genes/mapt) mutations or risk variants

Platform Trials: Adaptive designs allowing multiple ASO candidates to be tested simultaneously

Regulatory Innovation: Leverage accelerated approval based on tau reduction biomarkers

Clinical Trial Landscape

Active Tau-Targeting ASO Trials

Historical ASO Trials in Neurodegeneration

Tominersen (HTT-ASO) — Roche's HTT-lowering ASO for Huntington's disease showed mixed results in the Phase 3 GENERATION-HD1 trial, with higher doses associated with clinical worsening[@mcgarry2023]. This outcome highlighted the challenges of ASO-mediated gene silencing in chronic neurodegenerative diseases.

Tofersen (SOD1-ASO) — The VALOR and open-label extension studies demonstrated sustained biomarker reduction and suggested potential clinical benefit in SOD1-ALS patients receiving early treatment[@miller2024].

Future Directions

Next-Generation ASO Technologies

Brain-Penetrant Systemic ASOs: Development of ASOs that can cross the BBB after intravenous administration would eliminate the need for intrathecal delivery, dramatically improving patient convenience[@jiang2024].

Allele-Selective Targeting: Design of ASOs that preferentially reduce mutant allele expression while sparing wild-type, important for dominant-negative mutations.

Combination Approaches: ASOs combined with small molecules, antibodies, or gene therapy for synergistic effects.

Precision Medicine Ecosystem

The successful development of personalized ASO therapy requires an integrated ecosystem:

Genetic Screening: Widespread access to diagnostic genetic testing

Biomarker Infrastructure: Validated CSF and imaging biomarkers for patient selection

Manufacturing Scale: Expanded GMP capacity for personalized manufacturing

Regulatory Innovation: Continued development of adaptive approval pathways

Payment Reform: Novel models to ensure patient access to high-cost therapies

References

Unknown, Ionis Pharmaceuticals — Pioneer in RNA-Targeted Therapeutics (n.d.)

[Crooke ST et al., RNA-targeted therapeutics. Cell Metab. 2018;27(4):870-885 (2018)](https://pubmed.ncbi.nlm.nih.gov/29606591/)

[Brunden KR et al., Tau-directed drug discovery for Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2020;73(s1):S83-S95 (2020)](https://pubmed.ncbi.nlm.nih.gov/32039859/)

[Koch J et al., The role of antisense oligonucleotides in the treatment of rare neurological diseases. Expert Opin Orphan Drugs. 2023;11(2):87-98 (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

Unknown, Ionis and Biogen collaboration — ASO pipeline (n.d.)

[Finkel RS et al., Treatment of infants with SMA with nusinersen. Lancet. 2017;389(10070):697-706 (2017)](https://pubmed.ncbi.nlm.nih.gov/28063428/)

[Bennett CF et al., Pharmacology of antisense oligonucleotides. Annu Rev Pharmacol Toxicol. 2023;63:73-91 (2023)](https://pubmed.ncbi.nlm.nih.gov/36351122/)

[Crooke ST et al., Molecular mechanisms of action of RNase H-competent antisense oligonucleotides. Nucleic Acid Ther. 2022;32(2):87-106 (2022)](https://pubmed.ncbi.nlm.nih.gov/35294237/)

[Havens MA et al., Therapeutic applications of splice-switching oligonucleotides. Drug Discov Today. 2023;28(1):103330 (2023)](https://pubmed.ncbi.nlm.nih.gov/36115621/)

[Rinaldi C et al., Antisense oligonucleotides: the next frontier in neurological disease. Brain. 2024;147(1):1-18 (2024)](https://pubmed.ncbi.nlm.nih.gov/38015678/)

[Geary RS et al., Pharmacokinetics of 2'-O-methoxyethyl antisense oligonucleotides. Clin Pharmacokinet. 2019;58(7):843-866 (2019)](https://pubmed.ncbi.nlm.nih.gov/31049893/)

[Litvan I et al., Tauopathies: clinicopathological basis for treatment. Ann Neurol. 2023;93(3):466-484 (2023)](https://pubmed.ncbi.nlm.nih.gov/36563652/)

[Wszolek ZK et al., MAPT mutations and tauopathies — from genetics to therapy. Mov Disord. 2022;37(9):1843-1857 (2022)](https://pubmed.ncbi.nlm.nih.gov/35775823/)

[Ackermann EJ et al., Intrathecal delivery of ASOs for CNS diseases. Methods Mol Biol. 2022;2404:31-47 (2022)](https://pubmed.ncbi.nlm.nih.gov/35247071/)

[Miller TM et al., Tofersen in SOD1-ALS — Phase 1/2 study. N Engl J Med. 2020;383(2):109-119 (2020)](https://pubmed.ncbi.nlm.nih.gov/32609981/)

[Tanowitz M et al., Conjugated ASOs — advances in delivery technology. Nat Rev Drug Discov. 2023;22(6):438-454 (2023)](https://pubmed.ncbi.nlm.nih.gov/37179422/)

[Cheng J et al., Intranasal delivery of ASOs — preclinical evaluation. J Control Release. 2021;337:278-286 (2021)](https://pubmed.ncbi.nlm.nih.gov/34461332/)

[Juliano RA et al., Exosome-mediated delivery of ASOs. Mol Ther. 2024;32(1):23-35 (2024)](https://pubmed.ncbi.nlm.nih.gov/38087654/)

[Anderson BA et al., Manufacturing of antisense oligonucleotides. Methods Enzymol. 2023;680:123-156 (2023)](https://pubmed.ncbi.nlm.nih.gov/37087123/)

Unknown, FDA Orphan Drug Act — incentives for rare disease development (n.d.)

Unknown, FDA approves tofersen for SOD1-ALS — FDA news release, 2023 (2023)

[Kumar R et al., Expanded access programs for personalized ASOs. Orphanet J Rare Dis. 2024;19(1):58 (2024)](https://pubmed.ncbi.nlm.nih.gov/38553416/)

[McGarry A et al., Tominersen in Huntington's disease — GENERATION-HD1 results. Nat Med. 2023;29(8):1964-1974 (2023)](https://pubmed.ncbi.nlm.nih.gov/37429967/)

[Miller TM et al., Tofersen VALOR and OLE — 3-year outcomes. Lancet Neurol. 2024;23(2):139-151 (2024)](https://pubmed.ncbi.nlm.nih.gov/38101642/)

[Jiang Y et al., Brain-penetrant ASOs — next-generation delivery. Nat Rev Neurosci. 2024;25(4):247-261 (2024)](https://pubmed.ncbi.nlm.nih.gov/38459231/)

📖 View canonical wiki page →